Header

UZH-Logo

Maintenance Infos

First-line therapies in inflammatory bowel disease


Girardin, Marc; Manz, Michael; Manser, Christine; Biedermann, Luc; Wanner, Roger; Frei, Pascal; Safroneeva, Ekaterina; Mottet, Christian; Rogler, Gerhard; Schoepfer, Alain M (2012). First-line therapies in inflammatory bowel disease. Digestion, 86(Suppl. 1):6-10.

Abstract

BACKGROUND AND AIMS: Medical therapy of inflammatory bowel disease (IBD) is becoming more complex, given the increasing choice of drugs to treat Crohn's disease (CD) and ulcerative colitis (UC). We aimed to summarize the current guidelines for first-line treatments in IBD.
METHODS: An extensive literature search with focus on the guidelines of the European Crohn's and Colitis Organisation for the diagnosis and treatment of CD and UC was performed. First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol. The following drug categories were not included: cyclosporine and tacrolimus (not yet approved by Swissmedic for IBD treatment).
RESULTS: Treatment recommendations for the following clinically frequent situations are presented according to disease severity: ileocecal CD, colonic CD, proximal small bowel CD and perianal CD. For UC the following situations are presented: ulcerative proctitis, left-sided colitis and pancolitis.
CONCLUSIONS: We provide a summary on the use of first-line therapies for clinically frequent situations in patients with CD and UC.

Abstract

BACKGROUND AND AIMS: Medical therapy of inflammatory bowel disease (IBD) is becoming more complex, given the increasing choice of drugs to treat Crohn's disease (CD) and ulcerative colitis (UC). We aimed to summarize the current guidelines for first-line treatments in IBD.
METHODS: An extensive literature search with focus on the guidelines of the European Crohn's and Colitis Organisation for the diagnosis and treatment of CD and UC was performed. First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol. The following drug categories were not included: cyclosporine and tacrolimus (not yet approved by Swissmedic for IBD treatment).
RESULTS: Treatment recommendations for the following clinically frequent situations are presented according to disease severity: ileocecal CD, colonic CD, proximal small bowel CD and perianal CD. For UC the following situations are presented: ulcerative proctitis, left-sided colitis and pancolitis.
CONCLUSIONS: We provide a summary on the use of first-line therapies for clinically frequent situations in patients with CD and UC.

Statistics

Citations

16 citations in Web of Science®
24 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

191 downloads since deposited on 13 Mar 2013
55 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:13 Mar 2013 14:05
Last Modified:07 Dec 2017 20:35
Publisher:Karger
ISSN:0012-2823
Publisher DOI:https://doi.org/10.1159/000341951
PubMed ID:23051720

Download

Download PDF  'First-line therapies in inflammatory bowel disease'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 97kB
View at publisher
Download PDF  'First-line therapies in inflammatory bowel disease'.
Preview
Content: Published Version
Filetype: PDF
Size: 99kB